MedTrace Logo

Pentoxifylline and Lumbar Radiculopathy

NCT03060434 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2025-05-21

No results posted yet for this study

Summary

The objective of this prospective controlled crossover study is to evaluate the efficacy and safety of pentoxifylline per os (800 mg daily) in the management of lumbar radiculopathy

Conditions

  • Lumbar Radiculopathy
  • Lumbar Disc Herniation
  • Lumbar Disc Disease

Interventions

DRUG

Pentoxifylline Oral Tablet

patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid

DRUG

Ibuprofen

patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid

Sponsors & Collaborators

  • St Joseph University, Beirut, Lebanon

    lead OTHER

Principal Investigators

  • Joseph Maarrawi, MD, PhD · Hotel Dieu de France Hospital - Beirut, Lebanon, 16 6830

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2022-12-01
Completion
2026-12-01

Countries

  • Lebanon

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03060434 on ClinicalTrials.gov